智通财经APP获悉，3月6日，中国国家药监局药品审评中心(CDE)官网公示，第一三共(DSNKY.US)申报的1类新药DS-3939a获批临床，拟开发治疗实体瘤。公开资料显示，DS-3939a是一种靶向肿瘤相关MUC1的抗体偶联药物(ADC)，正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询，本次为该产品首次在中国获批临床。

截图来源：CDE官网

据悉，DS-3939a正是一种靶向TA-MUC1的ADC，基于第一三共的DXd平台开发。该产品的结构由人源化抗TA-MUC1抗体、酶切可切割的四肽连接体和具有高药抗比(DAR)的DNA拓扑异构酶I抑制剂(DXd)组成。本次这款创新ADC在中国获批临床，意味着其将在中国进入临床研究阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.